Comparison of Efficacy and Safety of Lispro and Aspart Evaluated by Continuous Glucose Monitoring System in Patients with Newly Diagnosed Type 2 Diabetes

Table 2

The effect of transient insulin intensive therapy with metformin on blood glucose fluctuation control compared group Asp and group Lis.

	Group Asp (51)	Group Lis (48)	value	value
24 h MBG (mmol/L)	6.49 ± 0.10	6.49 ± 0.15	0.032	0.975
SDBG (mmol/L)	1.30 ± 0.08	1.28 ± 0.06	0.157	0.876
MAGE (mmol/L)	3.33 ± 0.27	3.18 ± 0.19	0.703	0.484
NGE (times)	4.54 ± 0.27	4.60 ± 0.21	−0.185	0.853
>10 AUC (mmol/L/day)	0.04 ± 0.01	0.04 ± 0.01	−0.014	0.989
>10 time (%)	3.00 ± 0.86	3.00 ± 0.78	−0.142	0.887
<3.9 AOC (mmol/L/day)	0.00 ± 0.00	0.01 ± 0.00	−0.481	0.246
<3.9 time (%)	1.71 ± 0.42	2.27 ± 0.79	−0.956	0.524
≥3.9 and ≤10 AUC (mmol/L/day)	2.55 ± 0.10	2.67 ± 0.11	−0.193	0.439
≥3.9 and ≤10 time (%)	97.59 ± 2.48	94.81 ± 1.05	−0.63	0.315

Data were presented as means ± SD. MBG: mean glucose concentration (mmol/L); SDBG: the standard deviation of the MBG (mmol/L); MAGE: mean amplitude of glycemic excursions (mmol/L); NGE: number of glycemic excursion; >10 AUC: the incremental area under curve of glucose concentrations above 10.0 mmol/L (mmol/L per day); >10 time: the percentage of the time spend on glucose concentrations above 10.0 mmol/L; <3.9 AOC: the decremental area over curve of glucose concentrations below 3.9 mmol/L (mmol/L per day); <3.9 time: the percentage of the time spend on glucose concentrations below 3.9 mmol/L; ≥3.9 and ≤10 AUC: the incremental area under curve of glucose concentrations between 3.9 mmol/L and 10 mmol/L (mmol/L per day); ≥3.9 and ≤10 time: the percentage of the time spend on glucose concentrations between 3.9 mmol/L and 10 mmol/L.